Drugs / Tripotassium bismuth dicitrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02892409 Background | Sep 2016 → Apr 2017 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tripotassium bismuth dicitrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02892409 ↗ |
| Route | Oral | “tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily” NCT02892409 ↗ |